Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME, page-111

The thing I like about the the OPT-302 injections is that the trial periods and outcomes are relatively short and there is time to explore and adjust patient selection and trial design.

You will recall, this was kind of the opposite to Sirtex where they made some non-ideal trial designs and relied heavily on post hoc analysis after spending the good part of 5 years on each of those trials. This directional trial will be very helpful to maybe run a phase 2b trial to show a clear effect and that result on its own will add significantly value to the company without waiting on phase 3 study. There appears to be some low hanging fruit which they can pick off with this type of trial, imo.